The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2022 | alloHSCT in Hodgkin lymphoma post PD-1 inhibitors
Eleni Gavriilaki, MD, PhD, G Papanicolaou Hospital, Thessaloniki, Greece, talks on the use of allogeneic hematopoietic stem cell transplantation (alloHSCT) after PD-1 inhibitors in Hodgkin lymphoma (HL). There is currently little data regarding the safety and efficacy of alloHSCT in this setting and there are many concerns regarding the feasibility of this approach due to post-transplant complications. Two recent studies presented at EBMT showed promising results for patients with HL treated with a post-transplant cyclophosphamide (PTCy) conditioning regimen prior to alloHSCT. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
Disclosures
Dr Gavriilaki has served as a consultant and/or received honoraria from Alexion Pharmaceuticals, Omeros Corporation, and Sanofi. Dr Gavriilaki has received research support from Jazz Pharmaceuticals.
